share_log

XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders

XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders

xBiotech Inc. 's(納斯達克股票代碼:XBIT)上週市值上漲了5700萬美元,這使持有45%的散戶投資者和內部人士都受益
Simply Wall St ·  04/09 18:00

Key Insights

關鍵見解

  • XBiotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • 50% of the business is held by the top 7 shareholders
  • Insider ownership in XBiotech is 44%
  • xBiotech擁有大量散戶投資者的所有權,這表明關鍵決策受到廣大公衆股東的影響
  • 50% 的業務由前 7 名股東持有
  • xBiotech 的內部所有權爲 44%

Every investor in XBiotech Inc. (NASDAQ:XBIT) should be aware of the most powerful shareholder groups. With 45% stake, retail investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

xBiotech Inc.(納斯達克股票代碼:XBIT)的每位投資者都應該知道最強大的股東群體。散戶投資者擁有該公司的最大股份,持有45%的股份。換句話說,該集團面臨最大的上行潛力(或下行風險)。

Retail investors gained the most after market cap touched US$250m last week, while insiders who own 44% also benefitted.

上週市值觸及2.5億美元后,散戶投資者漲幅最大,而持有44%的內部人士也從中受益。

In the chart below, we zoom in on the different ownership groups of XBiotech.

在下圖中,我們放大了xBiotech的不同所有權組。

ownership-breakdown
NasdaqGS:XBIT Ownership Breakdown April 9th 2024
NASDAQGS: XBIT 所有權明細 2024 年 4 月 9 日

What Does The Institutional Ownership Tell Us About XBiotech?

關於xBiotech,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

As you can see, institutional investors have a fair amount of stake in XBiotech. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at XBiotech's earnings history below. Of course, the future is what really matters.

如你所見,機構投資者在xBiotech中擁有相當數量的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看xBiotech的收益記錄。當然,未來才是真正重要的。

earnings-and-revenue-growth
NasdaqGS:XBIT Earnings and Revenue Growth April 9th 2024
納斯達克GS: XBIT 收益和收入增長 2024 年 4 月 9 日

Hedge funds don't have many shares in XBiotech. Looking at our data, we can see that the largest shareholder is the CEO John Simard with 22% of shares outstanding. Thomas Gut is the second largest shareholder owning 13% of common stock, and W. McKenzie holds about 8.4% of the company stock. Interestingly, the third-largest shareholder, W. McKenzie is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.

對沖基金在xBiotech中持有的股票不多。從我們的數據來看,我們可以看到最大股東是首席執行官約翰·西瑪德,已發行股票的22%。托馬斯·古特是第二大股東,擁有13%的普通股,麥肯齊持有公司約8.4%的股份。有趣的是,第三大股東W. McKenzie也是董事會成員,這再次表明公司最大股東擁有強大的內部所有權。

On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

經過進一步檢查,我們發現公司一半以上的股份由前7名股東持有,這表明較大股東的利益在一定程度上被較小的股東所平衡。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。我們目前沒有收到分析師對該股的任何報道,因此該公司不太可能被廣泛持有。

Insider Ownership Of XBiotech

xBiotech 的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同國家對內部人士的定義可能略有不同,但董事會成員總是計算在內。公司管理層對董事會的回答,董事會應代表股東的利益。值得注意的是,有時高層管理人員自己也在董事會中。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

It seems insiders own a significant proportion of XBiotech Inc.. It has a market capitalization of just US$250m, and insiders have US$110m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

內部人士似乎擁有xBiotech Inc.的很大一部分股份。它的市值僅爲2.5億美元,內部人士以自己的名義持有價值1.1億美元的股票。我們可以說這表明了與股東的一致性,但值得注意的是,該公司仍然很小;一些內部人士可能已經創立了該公司。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 45% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散戶投資者在內的公衆擁有該公司45%的股份,因此不容忽視。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand XBiotech better, we need to consider many other factors. For instance, we've identified 3 warning signs for XBiotech (2 are a bit unpleasant) that you should be aware of.

擁有公司股份的不同群體總是值得考慮的。但是,爲了更好地了解xBiotech,我們需要考慮許多其他因素。例如,我們已經確定了xBiotech的3個警告信號(2個有點不愉快),你應該注意這些信號。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

當然,這可能不是最值得買入的股票。因此,您可能希望看到我們免費收集的具有良好財務狀況的有趣潛在客戶。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論